Evaxion picks gonorrhea as second target for vaccine candidate
![Lars Staal Wegner, CEO of Evaxion Biotech | Photo: Evaxion Biotech / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14206664.ece/ALTERNATES/schema-16_9/doc7lo72l7ruc1vl2c9h59.jpg)
Evaxion Biotech has announced that the firm has chosen sexually transmitted disease gonorrhea as the second target of its EVX-B2 vaccine candidate.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Evaxion Biotech's lung cancer candidate ready for clinic
For subscribers
GSK to invest USD 1.2bn in infectious disease battle
For subscribers